Advertisement
Sigma-Aldrich
Sigma-Aldrich

The Scientist

» clinical trials and ecology

Most Recent

image: Opinion: Upgrading Cancer Prevention

Opinion: Upgrading Cancer Prevention

By | April 1, 2015

Preemptive detection and intervention will be key to easing the growing burden of cancer, particularly in developing countries.

1 Comment

image: Ebola Vax Trial Update

Ebola Vax Trial Update

By | March 26, 2015

A novel Ebola vaccine being tested in China is safe and provokes a notable immune response in people, according to a Phase 1 trial.

0 Comments

image: Capsule Reviews

Capsule Reviews

By | March 1, 2015

Evolving Ourselves, The Man Who Touched His Own Heart, Bats, and The Invaders

1 Comment

image: Clinic Trial Problems Kept Mum

Clinic Trial Problems Kept Mum

By | February 11, 2015

Despite documented dysfunction in a number of studies, rarely do those problems get a mention in the resulting publications, according to a new study.

0 Comments

image: Ebola Drug Trial Canceled

Ebola Drug Trial Canceled

By | February 2, 2015

As the number of Ebola cases declines, Chimerix is unable to recruit enough patients for its trial in Liberia testing the antiviral drug brincidofovir.

0 Comments

image: Tamiflu Reviewed Again

Tamiflu Reviewed Again

By | January 30, 2015

The controversial antiviral drug earns better marks in the most recent analysis of the evidence. 

1 Comment

image: Ebola Update

Ebola Update

By | January 26, 2015

Vaccine trial to start in Liberia as early as next week; trial for experimental therapy also planned, but production is still limited

1 Comment

image: IOM Urges Data Sharing

IOM Urges Data Sharing

By | January 15, 2015

The Institute of Medicine says results from human clinical trials ought to be made available to independent researchers within 18 months.

0 Comments

image: 23andMe Partners with Pfizer

23andMe Partners with Pfizer

By | January 13, 2015

The personal genomics company strikes yet another deal to glean biomedically relevant information from its user data.

1 Comment

image: Spinoff Company to Develop Rare Disease Drugs

Spinoff Company to Develop Rare Disease Drugs

By | January 7, 2015

Maryland-based Vtesse will work with the US National Institutes of Health to advance treatments for Niemann-Pick Type C disease and other lysosomal storage disorders.

1 Comment

Advertisement

Popular Now

  1. The Mycobiome
    Features The Mycobiome

    The largely overlooked resident fungal community plays a critical role in human health and disease.

  2. Antibody Alternatives
    Features Antibody Alternatives

    Nucleic acid aptamers and protein scaffolds could change the way researchers study biological processes and treat disease.

  3. Holding Their Ground
    Features Holding Their Ground

    To protect the global food supply, scientists want to understand—and enhance—plants’ natural resistance to pathogens.

  4. Circadian Clock and Aging
    Daily News Circadian Clock and Aging

    Whether a critical circadian clock gene is deleted before or after birth impacts the observed aging-related effects in mice.

Advertisement
Advertisement
Life Technologies